xMAP technology: A benchmark for serological testing
10 Aug 2020In this white paper, Luminex outlines the applications and benefits of its xMAP technology for serological analysis. Multiplex serological testing can be particularly useful in a pandemic, as it can simultaneously analyze large numbers of antigens for large-scale screening and has the potential to replace traditional ELISA assays. Here, it is demonstrated that xMAP technology has become an established benchmark for running these multiplex serology tests.
Related Products
Request Quote for All Products
xMAP® SARS-CoV-2 Multi-Antigen IgG Assay (RUO)
LuminexThe xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results: S1 subunit of the spike protein Receptor Binding Domain (RBD) of the spike protein Nucleocapsid protein Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs. Versatile System Options: Can be used on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems, so you can use the platform that best fits your lab. Common Sample Types: Designed for use with plasma and serum samples, eliminating the need to implement additional collection protocols. For Research Use Only. Not for use in diagnostic procedures.
